NASH and thiazolidinediones: Not to be taken lightly

Journal of Hepatology

Volumn 47, Issue 4, 2007, Pages 451-453

  Dufour, Jean François ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; URSODEOXYCHOLIC ACID;

CLINICAL TRIAL; EDITORIAL; FATIGUE; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; LEG EDEMA; LIVER BIOPSY; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

BODY WEIGHT; FATTY LIVER; HEPATITIS; HUMANS; PPAR GAMMA; THIAZOLIDINEDIONES; WEIGHT GAIN;

EID: 34548234414     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.07.012     Document Type: Editorial

References (23)

1. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307
2. Balas B., Belfort R., Harrison S.A., Darland C., Finch J., Schenker S., et al. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol 47 (2007) 565-570
3. Ratziu V., Bonyhay L., Di Martino V., Charlotte F., Cavallaro L., Sayegh-Tainturier M.H., et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35 (2002) 1485-1493
4. Kim M, Wands J. Insulin pathway. In: Dufour J-F, Clavien PA, editors. Signaling pathways in liver diseases, 2005. p. 105-13.
5. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 444 (2006) 860-867
6. Genolet R, Michalik L, Wahli W. PPARs. In: Dufour J-F, Clavien PA, editors. Signaling pathways in liver dieases, 2005. p. 267-280.
7. Caldwell S.H., Hespenheide E.E., Redick J.A., Iezzoni J.C., Battle E.H., and Sheppard B.L. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96 (2001) 519-525
8. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., and Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38 (2003) 1008-1017
9. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39 (2004) 188-196
10. Ratziu V., Charlotte F., Jacqueminet S., Giral P., Podevin P., Serfaty L., et al. A one year randomized, placebo-controlled, double blind trial of rosiglitazone in non-alcoholic steatohepatitis: results of the FLIRT pilot trial. J Hepatol 44 (2006) S272
11. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108 (2003) 2941-2948
12. Thomas E.L., Brynes A.E., Hamilton G., Patel N., Spong A., Goldin R.D., et al. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol 12 (2006) 5813-5819
13. Miyazaki Y., Mahankali A., Matsuda M., Mahankali S., Hardies J., Cusi K., et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87 (2002) 2784-2791
14. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
15. Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
16. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
17. Psaty B.M., and Furberg C.D. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med 357 (2007) 67-69
18. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
19. Ekstedt M., Franzen L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006) 865-873
20. Dekker M.J., Lee S., Hudson R., Kilpatrick K., Graham T.E., Ross R., et al. An exercise intervention without weight loss decreases circulating interleukin-6 in lean and obese men with and without type 2 diabetes mellitus. Metabolism 56 (2007) 332-338
21. Ozcan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R.O., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313 (2006) 1137-1140
22. Lindor K.D., Kowdley K.V., Heathcote E.J., Harrison M.E., Jorgensen R., Angulo P., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39 (2004) 770-778
23. Dufour J.F., Oneta C.M., Gonvers J.J., Bihl F., Cerny A., Cereda J.M., et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 4 (2006) 1537-1543